

**A.G.P./Alliance Global Partners**  
590 Madison Ave., 28th Floor  
New York, NY 10022

December 21, 2023

VIA EDGAR

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

**Re: CNS Pharmaceuticals Inc. (the “Company”)  
Registration Statement on Form S-1 (File No. 333-275973) (the “Registration Statement”)**

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence via EDGAR on December 20, 2023, in which A.G.P / Alliance Global Partners as lead Placement Agent, joined the Company’s request for acceleration of the effective date of the above-referenced Registration Statement for 5:00 pm Eastern Time on December 21, 2023, or as soon thereafter as practicable, in accordance with Rule 461 under the Securities Act of 1933, as amended. The Company is no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.

Very truly yours,

A.G.P / Alliance Global Partners

By: /s/ Thomas J. Higgins  
Name: Thomas J. Higgins  
Title: Managing Director